A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Project: Research

NMA HREC Reference Number: HREC/2020/QMS/60595
NMA SSA Reference Number: SSA/60595/MonH-2020-209798(v1)
Monash Health Reference: RES-20-0000-244X

Status	Active
Effective start/end date	7/05/20 → 6/05/25

Project Details